Notice2022-10130
Advisory Committee on Immunization Practices (ACIP)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 10, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 90 (Tuesday, May 10, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 90 (Tuesday, May 10, 2022)]
[Notices]
[Pages 28011-28012]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-10130]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0065]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment.
DATES: The meeting will be held on May 19, 2022, from 11:00 a.m. to
4:00 p.m., EDT (times subject to change). The meeting will be webcast
live via the World Wide Web. Written comments must be received on or
before May 19, 2022.
ADDRESSES: You may submit comments identified by Docket No. CDC-2022-
0065 by either of the following methods:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments.
<bullet> Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027, Attn: May
19, 2022, ACIP Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the <a href="https://www.regulations.gov">https://www.regulations.gov</a> suitability policy will be posted
without change to <a href="https://www.regulations.gov">https://www.regulations.gov</a>, including any personal
information provided. For access to the docket to read background
documents or comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027, Telephone: (404)
639-8367; Email: <a href="/cdn-cgi/l/email-protection#28696b6178684b4c4b064f475e"><span class="__cf_email__" data-cfemail="6322202a33230007004d040c15">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less
than 15 calendar days' notice is being given for this meeting due to
the exceptional circumstances of the
[[Page 28012]]
COVID-19 pandemic and rapidly evolving COVID-19 vaccine development and
regulatory processes. The Secretary of Health and Human Services has
determined that COVID-19 is a Public Health Emergency. A notice of this
ACIP meeting has also been posted on CDC's ACIP website at: <a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a>. In addition, CDC has sent notice
of this ACIP meeting by email to those who subscribe to receive email
updates about ACIP.
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children program, along with
schedules regarding dosing interval, dosage, and contraindications to
administration of vaccines. Further, under provisions of the Affordable
Care Act, section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been approved by the CDC Director
and appear on CDC immunization schedules must be covered by applicable
health plans.
Matters to be Considered: The agenda will include discussions on
the use of COVID-19 vaccines. A recommendation vote(s) is scheduled.
Agenda items are subject to change as priorities dictate. For more
information on the meeting agenda, visit <a href="https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html">https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html</a>. The meeting will be webcast live via
the World Wide Web; for more information on ACIP, visit the ACIP
website: <a href="https://www.cdc.gov/vaccines/acip/index.html">https://www.cdc.gov/vaccines/acip/index.html</a>.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on May 10, 2022. Written comments must be received on
or before May 19, 2022.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes, including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the May 19, 2022, ACIP meeting must submit a
request at <a href="https://www.cdc.gov/vaccines/acip/meetings/index.html">https://www.cdc.gov/vaccines/acip/meetings/index.html</a> no
later than 11:59 p.m., EDT, May 17, 2022, according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email on May 18, 2022. To accommodate the significant interest
in participation in the oral public comment session of ACIP meetings,
each speaker will be limited to 3 minutes, and each speaker may speak
only once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-10130 Filed 5-6-22; 4:15 pm]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 10, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.